New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
12:06 EDTTSRO, FPRXFive Prime could be close to collaboration deal, says Wells Fargo
Wells Fargo says that after speaking to management, it believes Five Prime Therapeutics (FPRX) may be close to finalizing a collaboration deal with a pharma company relating to its preclinical immunooncology targets. Wells expects a near-term partnership to drive shares of Five Prime higher, and notes TESARO (TRSO) is up around 30% today following its collaboration announcement.
News For FPRX;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
07:44 EDTTSROAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
December 4, 2014
16:10 EDTFPRXFive Prime initiates dosing in Phase 1 trial of FPA144
Five Prime Therapeutics announced that the company has initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody. FPA144 is designed to inhibit tumor growth by preventing the binding of certain fibroblast growth factors to FGF receptor 2b and directly kill tumor cells in a process called antibody-dependent cell-mediated cytotoxicity. FPA144 is being developed initially as a monotherapy for refractory gastric cancer, a significant unmet medical need that may warrant an accelerated development and registration path. The Phase 1 clinical trial of FPA144 has two parts. The first part of the trial will enroll unselected patients with solid tumors to explore the safety of the drug and identify a dose for expansion to test in patients with gastric cancer. During the second part of the trial, Five Prime will enroll gastric cancer patients with FGFR2b protein overexpression or FGFR2 gene amplification in their tumors as identified through proprietary molecular diagnostic assays. Important endpoints of the trial include safety and overall response rate.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use